PhaseBio Pharmaceuticals Net Debt

Net Debt of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.

Highlights and Quick Summary

  • Net Debt for the quarter ending September 29, 2021 was $-46.6 Million (a -12.48% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt increased by 232.97%
  • Annual Net Debt for 2020 was $-14 Million (a -75.7% decrease from previous year)
  • Annual Net Debt for 2019 was $-57.5 Million (a 7.46% increase from previous year)
  • Annual Net Debt for 2018 was $-53.6 Million (a -2680.77% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of PhaseBio Pharmaceuticals

Most recent Net Debtof PHAS including historical data for past 10 years.

Interactive Chart of Net Debt of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-46.57 $-53.22 $-64.27
2020 $-13.99 $-23.78 $-38.24 $-44.7 $-13.99
2019 $-59.32 $-72.04 $-80.65 $-44.65 $-57.55
2018 $-53.55 $-16.84 $-53.55
2017 $2.08
2016 $-3.72

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.